The assessment of non‐inferiority in a gold standard design with censored, exponentially distributed endpoints

The objective of this paper is to develop statistical methodology for non-inferiority hypotheses to censored, exponentially distributed time to event endpoints. Motivated by a recent clinical trial in depression, we consider a gold standard design where a test group is compared with an active reference and with a placebo group. The test problem is formulated in terms of a retention of effect hypothesis. Thus, the proposed Wald-type test procedure assures that the effect of the test group is better than a pre-specified proportion Delta of the treatment effect of the reference group compared with the placebo group. A sample size allocation rule to achieve optimal power is presented, which only depends on the pre-specified Delta and the probabilities for the occurrence of censoring. In addition, a pretest is presented for either the reference or the test group to ensure assay sensitivity in the complete test procedure. The actual type I error and the sample size formula of the proposed tests are explored asymptotically by means of a simulation study showing good small sample characteristics. To illustrate the procedure a randomized, double blind clinical trial in depression is evaluated. An R-package for implementation of the proposed tests and for sample size determination accompanies this paper on the author's web page.

[1]  G. Freitag,et al.  Methods for Assessing Noninferiority with Censored Data , 2005, Biometrical journal. Biometrische Zeitschrift.

[2]  Meinhard Kieser,et al.  Planning and analysis of three-arm non-inferiority trials with binary endpoints. , 2007, Statistics in medicine.

[3]  Armin Koch,et al.  Hypothesis Testing in the “Gold Standard” Design for Proving the Efficacy of an Experimental Treatment Relative to Placebo and a Reference , 2004, Journal of biopharmaceutical statistics.

[4]  T. Schwartz,et al.  A two‐stage sample size recalculation procedure for placebo‐ and active‐controlled non‐inferiority trials , 2006, Statistics in medicine.

[5]  Sue-Jane Wang,et al.  A Regulatory Perspective on Choice of Margin and Statistical Inference Issue in Non‐inferiority Trials , 2005, Biometrical journal. Biometrische Zeitschrift.

[6]  S S Ellenberg,et al.  Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 1: Ethical and Scientific Issues , 2000, Annals of Internal Medicine.

[7]  Armin Koch,et al.  Discussion on “Establishing Efficacy of a New Experimental Treatment in the ‘Gold Standard’ Design” , 2005 .

[8]  S. Lange,et al.  Choice of delta: requirements and reality--results of a systematic review. , 2005, Biometrical journal. Biometrische Zeitschrift.

[9]  R. Dworkin,et al.  Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain , 2005, Neurology.

[10]  Man-Lai Tang,et al.  Tests of Noninferiority via Rate Difference for Three-Arm Clinical Trials with Placebo , 2004, Journal of biopharmaceutical statistics.

[11]  MD N. Canas,et al.  Reversible cervical hydromyelia in subacute combined degeneration , 2005, Neurology.

[12]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[13]  J A Lewis,et al.  Trials to assess equivalence: the importance of rigorous methods , 1996, BMJ.

[14]  A. Zangen,et al.  Screening for new antidepressants with fast onset and long‐lasting action , 2000 .

[15]  Eric R. Ziegel,et al.  Statistical Issues in Drug Development , 1997 .

[16]  R. Sysko,et al.  Placebo response in studies of major depression: variable, substantial, and growing. , 2002, JAMA.

[17]  Iris Pigeot,et al.  Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo. , 2003, Statistics in medicine.

[18]  R. D'Agostino,et al.  Non‐inferiority trials: design concepts and issues – the encounters of academic consultants in statistics , 2002, Statistics in medicine.

[19]  J Röhmel,et al.  Therapeutic equivalence investigations: statistical considerations. , 1998, Statistics in medicine.

[20]  A. Nierenberg,et al.  Evolution of remission as the new standard in the treatment of depression. , 1999, The Journal of clinical psychiatry.

[21]  Mark Rothmann,et al.  Design and analysis of non‐inferiority mortality trials in oncology , 2002, Statistics in medicine.